{"schema_version":"secwatch.filing_event.v1","accession":"0000012208-25-000004","form_type":"8-K","ticker":"BIO","cik":"0000012208","company_name":"BIO-RAD LABORATORIES, INC.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.123603+00:00","generated_at":"2026-05-26T22:06:07.845059+00:00","sec_items":["2.02","2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bio-Rad Q4 revenue down 2%; launches restructuring (5% workforce cut) and offers to acquire Stilla","bullets":["Q4 2024 revenue $667.5M vs $681.2M YoY; GAAP operating income $58.4M vs $95.3M.","Full-year 2024 revenue $2,566.5M vs $2,671.2M; non-GAAP op margin 12.9% vs 14.2%.","Restructuring plan eliminates ~5% of workforce; expected cost $45-50M, $30-35M charge in Q1 2025.","Binding offer to acquire all equity of Stilla Technologies (digital PCR); close expected by Q3 2025.","No deal value disclosed; acquisition subject to regulatory approvals and employee consultation."],"urls":{"canonical":"https://secwatch.observer/filing/0000012208-25-000004","json":"https://secwatch.observer/filing/0000012208-25-000004.json","markdown":"https://secwatch.observer/filing/0000012208-25-000004.md","text":"https://secwatch.observer/filing/0000012208-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/12208/000001220825000004/0000012208-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/12208/000001220825000004/bio-20250207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:06:07.845059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}